Brief report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2719-2723

  Shapira, Iuliana ^a   Andrade, Danieli ^b   Allen, Steven L ^a   Salmon, Jane E ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ARGATROBAN; ASPARTATE AMINOTRANSFERASE; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CIPROFLOXACIN; CLOPIDOGREL; COMPLEMENT COMPONENT C5; CYCLOPHOSPHAMIDE; D DIMER; ECULIZUMAB; FONDAPARINUX; HAPTOGLOBIN; HEMOGLOBIN; HIRULOG; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; LEPIRUDIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGRAPHY; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BELOW KNEE AMPUTATION; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; HEMATOMA; HEMIPARESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL NORMALIZED RATIO; LIVEDO RETICULARIS; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MALE; NEISSERIA MENINGITIDIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; STAPHYLOCOCCAL BACTEREMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOE GANGRENE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT MEMBRANE ATTACK COMPLEX; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PLASMA EXCHANGE; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84864485595     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34440     Document Type: Article

References (15)

1. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
2. Espinosa G, Bucciarelli S, Asherson RA, Cervera R,. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008; 34: 290-4.
3. Asherson RA, Cervera R, Merrill JT, Erkan D,. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost 2008; 34: 256-66.
4. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-54.
5. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J,. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-4.
6. Salmon JE, de Groot PG,. Pathogenic role of antiphospholipid antibodies. Lupus 2008; 17: 405-11.
7. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-9.
8. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-9.
9. Asherson RA, Espinosa G, Menahem S, Yinh J, Bucciarelli S, Bosch X, et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2008; 37: 366-72.
10. Girardi G, Redecha P, Salmon JE,. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-6.
11. Erre GL, Pardini S, Faedda R, Passiu G,. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008; 17: 50-5.
12. Richards A, Kavanagh D, Atkinson JP,. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states: the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007; 96: 141-77.
13. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 4123-8.
14. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-4.
15. Lonze BE, Singer AL, Montgomery RA,. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362: 1744-5.